Sugar Maple Asset Management’s Pfizer PFE Stock Holding History

Sugar Maple Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,620	Closed	-$43K	–	354
2024 Q4	$43K	Buy	+1,620	New	+$43.9K	0.03%	135

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sugar Maple Asset Management's PFE Position: Q1 2025 in Review

Sugar Maple Asset Management sold out of Pfizer (PFE) in Q1 2025, closing a stake of 1,620 shares — an estimated $43K sold.

Sugar Maple Asset Management first reported a position in PFE in Q4 2024 and held it in 1 quarter. The position peaked at $43K in Q4 2024. 2,931 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

Sugar Maple Asset Management reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
Sugar Maple Asset Management sold 1,620 Pfizer shares in Q1 2025, an estimated $43K.
Sugar Maple Asset Management first reported a position in Pfizer in Q4 2024 and held it in 1 quarter.
Sugar Maple Asset Management's Pfizer position peaked at $43K in Q4 2024.
2,931 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Sugar Maple Asset Management's 13F filing for Q1 2025, filed 10 Apr 2025.